Loss of animal insulin in Canada highlights how patients can be left behind

Wockhardt, the world’s last maker of porcine insulin (Hypurin), is shifting the product from vials to cartridges and will only reapply for Health Canada authorization if the regulator waives application fees of roughly CAD $44,269 to CAD $320,000; Health Canada has not committed to a waiver. The company discontinued vial sales in March 2025 and warned remaining vials expire this spring; advocates estimate 60–100 Canadians use animal insulin (Health Canada/Wockhardt cite fewer than 20), creating an imminent access risk and potential short-term import solutions (e.g., 90-day UK supply).

Analysis

This episode is a microcosm of how regulatory frictions (format-driven reauthorizations and fee structures) create acute scarcity for low-volume biologics: a handful of patients face outsized clinical harm while commercial incentives discourage any firm from absorbing that tail cost. The immediate window for resolution is short — days-to-weeks for a Health Canada statement on fee waivers or SAP facilitation, and 1–3 months for any negotiated workaround — so outcomes are binary and policy-driven rather than demand-driven.

Second-order competitive effects favor large vertically integrated players and pen/cartridge-platform suppliers. If regulators demand re-filings at scale, expect outsized incremental revenue pools for regulatory/CRO firms and for manufacturers that already control pen ecosystems (pen hardware + proprietary cartridges), while small legacy suppliers will be permanently squeezed out, accelerating concentration in the insulin supply chain over 6–24 months.

Policy reaction is the main tail risk: a sympathetic government intervention (fee waiver or emergency import carve-out) would resolve scarcity quickly and blunt the reshoring narrative, but a protracted bureaucratic stalemate would amplify public outrage and likely trigger legislative fixes or procurement programs that favor onshore capacity investments over the next 1–3 years. That bifurcation creates asymmetric short-term event risk and a longer-term structural trade toward players exposed to regulatory work and pen-platform capture.

Contrarian angle: the market underrates the political cost of denying last-resort therapies to identifiable constituents — expect Health Canada or Ottawa to find an administrative fix within 30–90 days once media/patient pressure peaks, which would temporarily benefit distributors and CROs more than incumbents that priced in permanent exits.

Key Decisions for Investors

• Buy Becton Dickinson (BDX) stock, 6–12 month horizon — thesis: cartridge/pen adoption and incremental consumable volume offsets modest downside if regulator forces continued vial use. Risk/reward: targeted upside 15–25% if cartridge demand accelerates; downside ~10–15% on device-competition risk or macro weakness.
• Buy IQVIA (IQV) 12-month call options (or stock) — thesis: regulatory filings and consulting work for format changes favor CRO/data vendors; catalyst: surge in low-volume reauthorizations. Risk/reward: asymmetric — small premium for calls with potential multi-bagger bid on contract flow; downside limited to option premium.
• Buy AmerisourceBergen (ABC) or McKesson (MCK), 3–6 month horizon — thesis: distributors win short-term import/compassionate-use flows if SAP/logistics are required. Risk/reward: modest revenue bump (single-digit % of EPS) but low downside as core distribution stable.
• Event-fade trade: if Health Canada remains silent >30 days, buy Canadian healthcare equities/exposure to domestic manufacturing announcements (select names on announcement) and short knee-jerk reshore beneficiaries — rationale: rapid policy fix likely removes momentum from reshoring/legislative proposals, compressing rhetoric-driven rallies.